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CD8 T lymphocytes appear to play a role in controlling human immunodeficiency virus (HIV) replication,
yet routine immunological assays do not measure the antiviral efficacy of these cells. Furthermore, it has been
suggested that CD8 T cells that recognize epitopes derived from proteins expressed early in the viral
replication cycle can be highly efficient. We used a functional in vitro assay to assess the abilities of different
epitope-specific CD8 T-cell lines to control simian immunodeficiency virus (SIV) replication. We compared
the antiviral efficacies of 26 epitope-specific CD8 T-cell lines directed against seven SIV epitopes in Tat, Nef,
Gag, Env, and Vif that were restricted by either Mamu-A*01 or Mamu-A*02. Suppression of SIV replication
varied depending on the epitope specificities of the CD8 T cells and was unrelated to whether the targeted
epitope was derived from an early or late viral protein. Tat28–35SL8- and Gag181–189CM9-specific CD8
 T-cell
lines were consistently superior at suppressing viral replication compared to the other five SIV-specific CD8
T-cell lines. We also investigated the impact of viral escape on antiviral efficacy by determining if Tat28–35SL8-
and Gag181–189CM9-specific CD8
 T-cell lines could suppress the replication of an escaped virus. Viral escape
abrogated the abilities of Tat28–35SL8- and Gag181–189CM9-specific CD8
 T cells to control viral replication.
However, gamma interferon (IFN-) enzyme-linked immunospot and IFN-/tumor necrosis factor alpha
intracellular-cytokine-staining assays detected cross-reactive immune responses against the Gag escape vari-
ant. Understanding antiviral efficacy and epitope variability, therefore, will be important in selecting candidate
epitopes for an HIV vaccine.
CD8 T lymphocytes are an important component of the
cellular immune response and play a role in controlling human
immunodeficiency virus/simian immunodeficiency virus (HIV/
SIV) replication. The depletion of circulating CD8 lympho-
cytes in SIV-infected macaques results in an increase in plasma
viral concentrations (25, 42, 59). CD8 T lymphocytes have
been shown to exert selective pressure on viral sequences in
vivo; immune escape variants are observed in both the acute (3,
7, 50) and chronic (6, 15, 23, 54) phases of HIV/SIV infection.
Furthermore, recent studies suggest that escape from CD8
T-cell responses exacts a cost in viral fitness, since transmitted
escape variants are not maintained in the absence of the se-
lecting major histocompatibility complex (MHC) class I allele
(2, 17, 33).
Several studies have shown associations between certain
MHC class I alleles and slow or rapid HIV/SIV disease pro-
gression, implying that these alleles restrict CD8 T-cell re-
sponses of varying effectiveness (8, 23, 26, 47, 48, 52, 61, 73,
74). However, it is still unknown which of the many HIV-
specific CD8 T lymphocytes actually contribute to the control
of viral replication. Despite technological advances and new
methodologies to detect and enumerate CD8 T-lymphocyte
responses against HIV/SIV, most of the current cellular assays
do not actually measure antiviral efficacy, the ability to sup-
press viral replication (70).
Initial reports using such functional assays demonstrated
that CD8 cells (63) and virus-specific cytotoxic T lymphocytes
(71) inhibited immunodeficiency virus replication in vitro.
Dendritic cells pulsed with inactivated autologous virus initi-
ated the expansion of virus-specific CD8 T cells that con-
trolled HIV replication (39). Based on these viral-replication
inhibition assays, it has been suggested that CD8 T lympho-
cytes directed against epitopes derived from early-expressed
proteins, particularly Nef and Rev, are more efficacious than
CD8 T lymphocytes directed against epitopes in late-ex-
pressed viral proteins (1, 65, 66, 72). However, a recent inves-
tigation demonstrated that Pol-specific CD8 T cells were also
effective at suppressing HIV replication (62). While most data
suggest that differences exist in the antiviral efficacies of CD8
T-cell populations, current HIV studies are limited to a small
number of well-defined clones.
Initially, we studied two immunodominant epitopes, Tat28–35
SL8 and Gag181–189CM9, which are bound by the commonly
studied Indian rhesus macaque MHC class I molecule Mamu-
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A*01 (3–6, 9, 17, 18, 32, 36, 45, 50–53, 60, 69). CD8 T-cell
lines directed against the Tat28–35SL8 epitope were consis-
tently more effective at suppressing SIVmac239 replication than
CD8 T-cell lines directed against the Gag181–189CM9 epitope
in our functional in vitro assay (36). This finding supported the
notion that CD8 T cells directed against early proteins are
more efficacious than their counterparts directed against late
proteins (1, 65, 66, 72).
In this study, we have conducted a broadened investiga-
tion to identify additional SIV-specific CD8 T-cell re-
sponses with strong antiviral activity. Furthermore, we have
directly compared the virus-suppressive abilities of CD8 T
cells that recognize early proteins to those of cells that rec-
ognize late-expressed proteins. Using the previously developed
viral-suppression assay (VSA), we compared the abilities of 26
SIV-specific CD8 T-cell populations directed against seven
epitopes in five SIV proteins, Tat, Nef, Gag, Env, and Vif, to
suppress viral replication. We found that suppression of SIV
replication varies depending on the epitope specificities of
the CD8 T-cell lines and cannot be generalized by protein
location or time of protein expression. The Tat28–35SL8- and
Gag181–189CM9-specific CD8
 T-cell lines were the most
effective at suppressing viral replication. Interestingly, low
plasma viremia in macaques used to generate the SIV-spe-
cific CD8 T-cell lines was not predictive of effective viral
suppression.
We also investigated the effect viral escape had on the abil-
ities of Tat28–35SL8- and Gag181–189CM9-specific CD8
 T cells
to suppress SIV replication. Recent studies of HIV have ob-
served the ability of antigen-specific CD8 T lymphocytes to
recognize variant peptides by using gamma interferon (IFN-)
production as the readout, providing encouragement that the
immune system may be able to cope with viral escape (22, 24, 46,
64). Similarly, we detected cytokine responses to a variant Gag
peptide in both IFN- enzyme-linked immunospot (ELISPOT)
and IFN-/tumor necrosis factor alpha (TNF-) intracellular-
cytokine-staining (ICS) assays. However, the cross-reactive cy-
tokine response to the variant Gag peptide did not predict the
abilities of Gag181–189CM9-specific CD8
 T-cell lines to sup-
press viral replication of an SIV escape variant. This illustrates
the profound effect of viral escape on abrogating the ability of
CD8 T lymphocytes to suppress viral replication. Researchers
have also claimed the detection of cross-clade HIV-specific
CD8 T-cell responses on the basis of cytokine production
assays alone (13, 21, 68). Our results suggest that such findings
may be misleading unless confirmed by functional assays.
MATERIALS AND METHODS
Animals and viruses. Indian rhesus macaques (Macaca mulatta) were identi-
fied as Mamu-A*01 and/or Mamu-A*02 by sequence-specific primer DNA
amplification (PCR-SSP), as previously described (32, 37). SIV-specific CD8
T-cell lines were derived from Mamu-A*01 and/or Mamu-A*02 macaques
infected with the molecularly cloned virus SIVmac239, GenBank accession no.
M33262 (28). Naı¨ve macaques were used as a source of peripheral blood mono-
nuclear cells (PBMC) for in vitro SIV infections.
For in vitro SIV infections, CD8-depleted PBMC were infected with SIVmac239
(28) or an engineered escape variant virus based on SIVmac239 (17). This variant
virus contained point mutations in two known Mamu-A*01 epitopes, Tat28–35SL8
and Gag181–189CM9, and contained the previously identified compensatory muta-
tions required for replication of the Gag mutant (18, 53).
SIV-infected animals were maintained at the National Primate Research Cen-
ter (University of Wisconsin—Madison) and cared for according to the regula-
tions and guidelines of the University of Wisconsin Institutional Animal Care
and Use Committee.
Quantification of vRNA in plasma. Viral RNA (vRNA) was isolated from
EDTA-anticoagulated plasma and detected in quantitative reverse transcription-
PCR (QRT-PCR) using a modification of a published protocol with a one-step
QRT-PCR kit (Invitrogen, Carlsbad, CA) (12). The final reaction mixtures
(20-l total volume) contained 0.2 mM of each deoxynucleoside triphosphate, 5
mM MgSO4, 0.015% bovine serum albumin (Sigma, St. Louis, MO), 150 nano-
grams random hexamer primers (Promega, Madison, WI), 0.8 l SuperScript III
reverse transcriptase and Platinum Taq DNA polymerase in a single enzyme mix,
600 nM of each amplification primer—forward (SIV1552), 5-GTCTGCGTCATC
TGGTGCATTC-3; reverse (SIV1635), 5-CACTAGCTGTCTCTGCACTATGT
GTTTTG-3—and 100 nM probe 5-6-carboxyfluorescein-CTTCCTCAGTGTGT
TTCACTTTCTCTTCTGCG-6-carboxytetramethylrhodamine-3. Temperature
cycling was performed on the LightCycler 1.2 (Roche, Indianapolis, IN) with slightly
altered parameters. The reverse transcriptase reaction was performed at 37°C for
15 min and then at 50°C for 30 min. An activation temperature of 95°C for 2 min
was followed by 50 amplification cycles of 95°C for 15 seconds and 62°C for 1 min
with ramp times set to 3° per second. Data were acquired and analyzed using
LightCycler 4.0 software.
Each QRT-PCR assay was run with a set of internal standards made up of a
dilution series of synthetic transcript containing a fragment of the SIV gag gene.
The theoretical concentrations of these standards range from 15 million copy eq
to 3 copy eq per sample. Copy numbers for samples were determined by inter-
polation onto the standard curve using the LightCycler software version 4.0.
The interassay variation in observed crossing points for each point on the
standard curve is less than 2%. Each assay is also run with an internal plasma
standard to control for both vRNA isolation and detection in QRT-PCR. The
interassay variability in the crossing point for this standard is 2.8%, and its
observed concentration (average, 179,000 copy eq/ml) varies by 48%. Under
normal assay conditions, the quantification threshold for this assay is 30 vRNA
copy eq/ml.
Generation and maintenance of CD8 T-cell lines. Peptide-specific CD8
T-cell lines were generated using previously described methods (67). Briefly,
PBMC were separated from whole heparin- or EDTA-treated blood by Ficoll-
Paque PLUS (GE Health Sciences, Piscataway, NJ) density centrifugation.
CD8 cells were separated from freshly isolated PBMC using the CD8 nonhu-
man primate microbead kit (Miltenyi Biotec, Auburn, CA) and the Miltenyi
Biotec AutoMACS magnetic cell separation unit according to the manufacturer’s
protocol. Fresh, unseparated PBMC were also used to start CD8 T-cell lines.
Autologous B-lymphoblastoid cell lines (BLCLs) were used as antigen-present-
ing cells. BLCLs were pulsed with 1 M of the relevant SIV-specific peptide for
1 to 2 h at 37°C, washed twice, and irradiated (9,000 rads). BLCLs were then
mixed with either whole or CD8-enriched PBMC at a ratio of 1:1 in RPMI 1640
(Cambrex, Walkersville, MD) supplemented with L-glutamine (Mediatech,
Herndon, VA), antibiotic-antimycotic solution (Mediatech), and 15% fetal bo-
vine serum (R15; HyClone, Logan, UT) with 10 ng/ml of recombinant human
interleukin-7 (Sigma-Aldrich, St. Louis, MO) and incubated for 48 h. The cells
were cultured with R15 containing 100 units of interleukin-2/ml (NIH AIDS
Research and Reference Reagent Program, Germantown, MD) every 3 to 5 days
thereafter. The CD8 T-cell lines were restimulated using peptide-pulsed, irra-
diated BLCL every 7 to 14 days. CD8 T-cell lines were routinely tested for
epitope specificity after 14 days in culture by either ICS or MHC class I
tetramer assays. MHC class I tetramer staining was performed as previously
described (38).
VSA. We performed in vitro VSAs as previously described (36). Briefly, the
target population consisted of CD8-depleted, phytohemagglutinin-stimulated
lymphocytes that were infected with SIVmac239 (28), or an engineered CD8
T-cell escape variant virus based on SIVmac239 (17), at a multiplicity of infection
of 5  105. We used in vitro-stimulated epitope-specific CD8 T-cell lines that
were sorted or grown to a high specificity (91%) as effector cells. All CD8
T-cell lines used were less than 6 months old, and more than half of the data were
derived from primary cell lines that underwent in vitro stimulation for approxi-
mately 2 months. Under these conditions, the age of the CD8 T-cell line did not
appear to impact its ability to suppress SIV replication (data not shown).
We added 5.0  105 CD8-depleted, phytohemagglutinin-stimulated lympho-
cytes (targets) to each well of a 24-well plate. The effector cells (CD8 T-cell
lines) were added to wells at effector-to-target (E:T) ratios of 1:10 and 1:20.
These E:T ratios reflect the maximum possible number of potentially infectible
target cells. The final volume of cell culture medium was 2 ml and contained 50
U/ml of interleukin-2 (NIH AIDS Research and Reference Reagent Program,
Germantown, MD). The cocultures were maintained for 8 days. Every 2 days, 0.5
ml supernatant was collected and replaced with fresh medium to determine
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vRNA concentrations. At the end of the assay (day 8), intracellular Gag p27
staining was performed on the coculture to measure SIVmac239 infection, as
previously described (36).
We cocultured MHC-mismatched effector and target cells as controls in each
assay (36). Using MHC-mismatched effector and target cells, we observed neg-
ligible reduction in SIV replication compared to wells that contained only in-
fected target cells (data not shown).
ICS assay. SIV-specific CD8 T-cell lines were used in TNF- and IFN- ICS
assays as previously described (67). Briefly, each test contained 2  105 CD8 T
cells and 0.5  105 to 1  105 autologous BLCLs. As a positive control, phorbol
myristate acetate (1 g/ml) with ionomycin (2 g/ml; Sigma-Aldrich) was used.
Individual Mamu-A*01- or Mamu-A*02-restricted minimal optimal peptides
were used at a concentration of 5 M or in serial 10-fold dilutions from 5 M to
5 pM. Approximately 2  105 lymphocyte-gated events were acquired on a
FACSCalibur (BD Biosciences) and analyzed using FlowJo software 6.4.1 (Tree-
Star). All values were normalized by subtracting the background level staining
(negative control of CD8 T-cell lines in media without stimulation).
IFN- ELISPOT assay. PBMC were separated from whole heparin- or EDTA-
treated blood by Ficoll-Paque PLUS (GE Health Sciences) density centrifuga-
tion. The PBMC were used directly in precoated ELISpotPLUS kits (MABTECH
Inc., Mariemont, OH) for the detection of monkey IFN- according to the
manufacturer’s protocols. Briefly, 1.0  105 PBMC were used per well and
incubated for 14 to 18 h at 37°C in 5% CO2. As a positive control, 5 g/ml of
concanavalin A (Sigma Chemical, St. Louis, MO) was added to the cells, and a
negative control of no peptide was also included on each plate. Peptides were
used at 10 M or in serial 10-fold dilutions from 10 M to 10 pM. All tests were
performed in triplicate.
Wells were imaged with an AID ELISPOT reader (AID, Strassberg, Ger-
many), counted with AID EliSpot Reader version 3.2.3, and analyzed as previ-
ously described (38). Spots were counted by an automated system with set
parameters for size, intensity, and gradient. Background (the mean of wells
without peptide stimulation) levels were subtracted from each well on the plate.
A response was considered positive if the mean number of spot-forming cells
(SFC) from triplicate sample wells exceeded background plus 2 standard devia-
tions.
Assay results are shown as SFC per 1  106 cells. Responses of 	50 SFC per
1  106 cells were not considered positive. Wells containing concanavalin A
(positive control) were always greater than 1,000 SFC per 1  106 PBMC.
RESULTS
Characteristics of CD8 T-cell populations against seven
CD8 T-cell epitopes in the viral-suppression assay. Previ-
ously, we developed an in vitro VSA to examine the antiviral
efficacies of CD8 T-cell populations that recognized two im-
munodominant Mamu-A*01-restricted epitopes, Tat28–35SL8
and Gag181–189CM9 (36). We found that the Tat28–35SL8-spe-
cific CD8 T-cell response was highly effective in suppressing
SIV replication compared to CD8 T cells directed against the
Gag181–189CM9 epitope. This supported the previously sug-
gested idea that CD8 T lymphocytes directed against early
proteins are better at controlling viral replication than CD8 T
lymphocytes directed against proteins expressed later in the
viral replication cycle (1, 65, 66, 72). We sought to identify
additional CD8 T-cell populations capable of effective virus
suppression. Mamu-A*01 and Mamu-A*02 macaques are
routinely studied in vaccine and pathogenesis experiments due
to the high frequency of these alleles, the knowledge of several
well-defined CD8 T-cell epitopes, and the availability of
MHC class I tetrameric reagents (3–6, 9, 17, 18, 32, 36, 38, 45,
49, 51–53, 58, 60, 69).
We selected seven common SIV-specific CD8 T-cell
epitopes restricted by Mamu-A*01 and Mamu-A*02 for our
investigation (Table 1). These epitopes are located within two
early-expressed SIV proteins (Tat and Nef) and three late-
expressed viral proteins (Gag, Env, and Vif) (30, 31, 55, 57).
Previous investigations detected viral sequence variation in all
of these CD8 T-cell epitopes (3, 5, 6, 38, 45, 49–51, 67). The
timing of viral escape ranged from 4 weeks postinfection, in the
cases of the Tat and Nef epitopes, to approximately 1 year
postinfection for selected Gag and Vif epitopes (Table 1).
As a marker for disease progression status, SIV viral loads
(vRNA copies/ml of plasma) at the time of CD8 T-cell line
generation are indicated in Table 2 for each macaque. We
generated CD8 T-cell lines from at least two animals for each
of the seven SIV-specific CD8 T-cell epitopes (Table 2). With
the exception of the Env620–628TL9 epitope, each epitope-
specific CD8 T-cell line was derived from at least one elite-
controller (EC) macaque, an animal maintaining chronic-phase
SIV viremia below 1,000 vRNA copies/ml (73). Some previously
published data on Tat28–35SL8- and Gag181–189CM9-specific
CD8 T-cell viral suppression was incorporated for the disease
progression comparison (36).
Effective suppression of viral replication by two SIV-specific
CD8 T-cell populations. Previous studies showed differences in
antiviral efficacy between HIV-specific CD8 T-cell clones di-
rected against early proteins versus late proteins (1, 65, 66, 72).
Therefore, we hypothesized that CD8 T cells directed against
SIV epitopes in early proteins might be more effective at sup-
pressing viral replication than those directed against epitopes in
late proteins. We generated CD8 T-cell lines that recognized
two early-protein epitopes (Tat28–35SL8 and Nef159–167YY9)
and five late-protein epitopes (Gag181–189CM9, Gag71–79GY9,
Env620–628TL9, Env788–795RY8, and Vif97–104WY8). Epitopes
within Gag, Nef, and Env were of particular interest due to the
inclusion of the genes in recent CD8 T-cell-based vaccines (4–6,
9, 19, 34, 41, 43, 45, 60, 69).
Our analysis included seven SIV epitopes restricted by Mamu-
A*01 or Mamu-A*02 (Table 1). Tat28–35SL8-specific CD8
 T-
cell populations were effective at viral suppression (Fig. 1 and
Table 2), as we have described before (36). Tat28–35SL8-specific
CD8 T-cell lines from four of the five animals tested reduced
viral production and Gag p27 target cells by 55% (Fig. 1).
CD8 T cells directed against Gag181–189CM9 demonstrated the
second-highest levels of viral suppression, in the range of 32 to
90% reduction. Env620–628TL9-specific CD8
 T cells did not
suppress viral replication. Moreover, none of the four Mamu-
A*02-restricted CD8 T-cell responses consistently sup-
pressed viral replication 50% in the VSA. These included
four CD8 T-cell lines directed against Nef159–167YY9, although
Nef is an early SIV protein (Fig. 1). Effective suppression was
not simply due to a higher frequency of epitope-specific CD8
T cells in the coculture, as the frequencies were typically com-
parable when tested at the end of each assay (data not shown).
TABLE 1. Characteristics of epitope-specific CD8 T cells
studied in the VSA
Protein Amino acidpositions
Short
name Sequence
MHC class I
restriction
Earliest
detected viral
variation (wk)
Tat 28–35 SL8 STPESANL Mamu-A*01 4
Vif 97–104 WY8 WTDVTPNY Mamu-A*02 57
Nef 159–167 YY9 YTSGPGIRY Mamu-A*02 4
Gag 71–79 GY9 GSENLKSLY Mamu-A*02 59
Gag 181–189 CM9 CTPYDINQM Mamu-A*01 18
Env 788–795 RY8 RTLLSRVY Mamu-A*02 32
Env 620–628 TL9 TVPWPNASL Mamu-A*01 14
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Of the five CD8 T-cell populations directed against late-
expressed proteins, effector cells recognizing Gag181–189CM9
displayed the highest levels of viral suppression (Fig. 1 and
Table 2). Interestingly, the CD8 T-cell response directed
against Gag71–79GY9 was not as effective as the Gag181–189CM9-
specific CD8 T-cell population. These results suggest that anti-
viral efficacy may be independent of the viral protein from which
the epitope is derived. Rather, antiviral efficacy should be eval-
TABLE 2. Disease statuses of SIV-infected macaques used to generate CD8 T-cell lines and representative antiviral efficacies
of the CD8 T-cell lines on day 8 of the VSA at an E:T ratio of 1:10
Animal SIV-specific CD8 T-cell line
Parameters near time of CD8 T-cell
line generation Percent reduction in SIV:
No. of wk
infected
Viral load (no. of
vRNA copies/ml)
vRNA
copies/ml
Gag p27
cells
95061a Gag 181–189 CM9 253 	50 83 76
95061a Tat 28–35 SL8 290 	50 77 55
95061a Env 788–795 RY8 288 	50 61 0
95061a Nef 159–167 YY9 288 	50 1 0
95061a Gag 71–79 GY9 266 109 72 24
98014a Nef 159–167 YY9 96 	50 0 0
98016a Vif 97–104 WY8 111 	50 2 2
98016a Gag 71–79 GY9 96 323 7 0
98016a Nef 159–167 YY9 96 323 0 0
98016a Env 788–795 RY8 136 353 0 0
2125 Tat 28–35 SL8 42 158,000 99 99
2125 Gag 181–189 CM9 42 158,000 90 84
2125 Env 622–630 TL9 42 158,000 47 0
2128 Tat 28–35 SL8 18 190,000 98 98
2128 Env 788–795 RY8 47 457,000 28 14
2128 Nef 159–167 YY9 47 457,000 10 0
2128 Gag 71–79 GY9 71 461,000 52 44
01008 Env 788–795 RY8 71 40,400 0 0
01008 Vif 97–104 WY8 71 40,400 0 0
01008 Env 622–630 TL9 53 89,300 0 0
97110 Gag 181–189 CM9 39 65,100 45 32
97110 Env 788–795 RY8 32 126,000 0 0
97110 Tat 28–35 SL8 16 569,000 38 0
01034 Env 622–630 TL9 54 837,000 44 14
97044 Env 788–795 RY8 66 1,610,000 64 28
2095 Tat 28–35 SL8 172 2,580,000 98 90
a Elite-controller macaque (maintaining chronic-phase viral load of 	1,000 viral RNA copies/ml).
FIG. 1. Percent reduction of Gag p27 target cells following an 8-day coculture with SIV-specific CD8 T-cell lines at an E:T ratio of 1:10.
Twenty-six epitope-specific CD8 T-cell lines directed against seven SIV epitopes (Tat28–35SL8, Gag181–189CM9, Gag71–79GY9, Env788–795RY8,
Env620–628TL9, Vif97–104WY8, and Nef159–167YY9) were used in the VSA. These CD8
 T-cell lines were derived from 10 SIV-infected Indian
rhesus macaques. The black bars indicate the average reduction for each SIV-specific CD8 T-cell response. Exact values are listed in Table 2.
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uated for each epitope of interest. The Env620–628TL9-,
Env788–795RY8-, and Vif97–104WY8-specific CD8
 T-cell lines
were ineffective at suppressing SIV replication (typically
	20% reduction).
Disease status does not appear to predict the ability of
CD8 T cells to suppress SIV replication. We also investigated
the potential impact of viral replication (vRNA copies/ml) at
the time the CD8 T-cell lines were generated on antiviral
efficacy. We had previously observed some variability among
animals in the ability of Tat28–35SL8-specific CD8
 T cells to
suppress SIV replication (36). To address this question, we
generated CD8 T-cell lines from macaques in various stages
of disease progression, including three EC macaques, 95061,
98014, and 98016, that controlled SIV replication at 	1,000
vRNA copies/ml (Table 2). We hypothesized that CD8 T-cell
lines from EC macaques would be particularly effective at
suppressing SIVmac239 replication.
Remarkably, CD8 T-cell lines generated from elite-con-
troller macaques were not always effective suppressors (Table
2). For instance, Tat28–35SL8-specific CD8
 T cells derived
from animal 95061, with a viral load of 	50 vRNA copies/ml,
did not suppress SIV replication as effectively as Tat28–35SL8-
FIG. 2. Recognition of wild-type and mutant epitopes in Gag and Tat as measured by IFN-/TNF- ICS and IFN- ELISPOT assays.
(A) Binding (50% inhibitory concentrations [IC50]) of the wild-type and variant peptides to Mamu-A*01 from a previous study (17). (B and C)
IFN-/TNF- ICS assay results for recognition of wild-type and escape variant peptides using Gag181–189CM9- (B) and Tat28–35SL8-specific
(C) CD8 T-cell lines derived from macaques 95061 and 97110, respectively. The data were normalized against the cytokine production when the
highest wild-type peptide concentration was used. This value was considered the maximal cytokine response and was labeled as 100%. (D and E)
Ex vivo IFN- ELISPOT assay results for recognition of wild-type and escape variant peptides using freshly isolated PBMC from macaque 95061
to test Gag reactivity (D) and from macaque 97110 to test Tat reactivity (E). Mean values from triplicate wells were calculated for each assay. The
background, the mean of wells without peptide, was subtracted from each well. Mean responses of 	50 SFC per 1  106 cells were not considered
positive. The error bars in panels D and E indicate standard deviations for the triplicate wells.
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specific CD8 T-cell lines derived from progressor macaques
2125 and 2128. Despite the high plasma virus RNA concen-
trations at the time the CD8 T-cell lines were generated,
Tat28–35SL8-specific cell lines from macaques 2125 and 2128
reduced vRNA concentrations and Gag p27 target cells
90% (Table 2). None of the four Mamu-A*02-restricted re-
sponses had appreciable levels of viral suppression, despite the
derivation of several SIV-specific CD8 T-cell lines from elite
controllers. These included CD8 T-cell lines directed against
the early protein Nef159–167YY9. Similarly, no correlation was
observed between CD4 counts at the time of cell line genera-
tion and the ability of CD8 T cells to suppress SIV replication
(data not shown).
Impact of viral escape on CD8 T-cell antiviral efficacy. It is
well established that CD8 T lymphocytes select for viral es-
cape variants (3, 5–7, 15, 23, 50, 54). Recent reports demon-
strated that CD8 T lymphocytes can mount responses to
variant peptides in cytokine production assays, implying that
HIV/SIV-specific CD8 lymphocytes can recognize mutant
epitopes (22, 24, 46, 64). Recent studies also quantified the
cross-clade reactivities of cellular immune responses to HIV using
the same assays (13, 21, 68). However, since they use PBMC or
epitope-specific CD8 T-cell lines pulsed with excessive amounts
of synthetic peptide, these routine immunological assays do not
reflect natural antigen processing and presentation. Therefore,
we investigated the abilities of our two most effective CD8 T-cell
lines, Tat28–35SL8 and Gag181–189CM9, to recognize escape vari-
ants commonly generated in vivo (3, 5, 6, 17, 18, 50, 51, 53).
A previous study found that the two mutations at positions 1
and 8 of the Tat epitope (STPESANL to PTPESANQ) essen-
tially abrogated peptide binding to Mamu-A*01 (Fig. 2A) (17).
However, while the position 2 amino acid substitution in the
Gag epitope (CTPYDINQM to CAPYDINQM) diminished
MHC class I binding, this variant peptide still bound at a
biologically relevant affinity of 354 nM (50% inhibitory con-
centration).
Based upon the previous binding analysis of the escape
variant epitopes, we hypothesized that we would observe
some recognition of the Gag escape variant and none with
the Tat escape variant. We first tested for peptide cross-
reactivity in IFN-/TNF- ICS assays using Gag181–189CM9-
and Tat28–35SL8-specific CD8
 T-cell lines (Fig. 2B and C).
The Gag variant peptide displayed cross-reactivity at a pep-
tide concentration range of 10,000 nM to 100 nM, while the
Tat escape variant was only weakly recognized at the highest
peptide concentration (Fig. 2B and C). To confirm these
results, we then tested the recognition of the variant pep-
tides in ex vivo IFN- ELISPOT assays using freshly isolated
PBMC. At a peptide concentration of 100 nM, the Gag
escape variant induced cytokine secretion (Fig. 2D). Re-
sponses to the wild-type and variant Gag peptides were
equal in magnitude at the highest peptide concentration. In
contrast, the Tat escape variant showed minimal cytokine
reactivity and only at the highest peptide concentration (Fig.
2E). The responses to variant peptides in IFN- ELISPOT
were likely due to recognition of the variant peptide (cross-
reactivity) and not the stimulation of a de novo response
against the mutant peptides. When both peptides were
tested in the same well, the number of SFC/106 PBMC did
not exceed the number of SFC seen when either peptide was
added alone (data not shown). Our results, in conjunction
with previously published work (22, 24, 46, 64), suggested
the possibility that the Gag181–189CM9-specific CD8
 T-cell
lines might be effective at suppressing an SIV escape
variant.
To directly assess the abilities of epitope-specific CD8 T
cells to control the replication of the mutant virus, we used a
variant of SIVmac239 (17) that contained escape mutations in
both Tat28–35SL8 and Gag181–189CM9 to infect target cells
(Fig. 3). As a control to determine whether the CD8 T cells
used were still capable of suppressing viral replication, CD8
target cells were also infected with wild-type SIVmac239. As
expected, both the Gag181–189CM9 and Tat28–35SL8-specific
CD8 T cells effectively suppressed wild-type SIVmac239 rep-
lication (Fig. 3). However, when the escape mutant SIV was
used, neither of these CD8 T-cell lines suppressed viral rep-
lication in four independent assays. We observed similar trends
at an E:T ratio of 1:20 (data not shown). This poor suppression
was particularly unexpected for the Gag181–189CM9-specific
CD8 T cells. The variant epitope still bound with a biologi-
cally relevant affinity, and the variant peptide stimulated both
SIV-specific CD8 T-cell lines and PBMC in IFN-/TNF-
ICS and IFN- ELISPOT assays, respectively (Fig. 2). This
inability of Gag181–189CM9-specific CD8
 T cells to suppress
the replication of the mutant virus stresses the importance of
functional assays that incorporate natural antigen processing
and presentation to evaluate the antiviral efficacies of epitope-
specific CD8 T-cell responses. These data also reemphasize
the importance of viral escape in evading host immune re-
sponses.
DISCUSSION
Unlike studies involving antibody responses in which neu-
tralization assays distinguish effective antibodies from ineffec-
tive ones, most current assays involving CD8 T cells do not
measure antiviral efficacy (70). We recently developed a func-
tional in vitro VSA to assess the ability of CD8 T cells to
control SIV replication and to study the impact of viral varia-
tion (36). This new assay has enabled us to expand upon pre-
vious HIV studies, which hinted at differences in antiviral ef-
ficacy among various CD8 T-cell populations (1, 62, 65, 66,
71, 72). We used our viral-suppression assay to examine the
antiviral efficacies of seven common CD8 T-cell responses
against epitopes restricted by two high-frequency MHC class I
alleles, Mamu-A*01 and Mamu-A*02 (Table 1). These CD8
T cells recognized epitopes from both early- and late-expressed
viral proteins. Twenty-six epitope-specific CD8 T-cell lines
were derived from 10 SIVmac239-infected macaques with dif-
fering disease statuses, including three elite-controller ma-
caques. We also examined the abilities of CD8 T cells to
suppress the replication of viruses containing common escape
mutations in two immunodominant Mamu-A*01-restricted
CD8 T-cell epitopes.
We found that suppression of SIV replication varied, de-
pending on the epitope specificity of the CD8 T cell (Fig. 1
and Table 2). Furthermore, this suppressive ability was not
related to whether the epitope was derived from an early- or
late-expressed viral protein. Even in our broadened investiga-
tion, Tat28–35SL8-specific CD8
 T cells remained the most
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effective at suppressing viral replication, as we had shown in
our initial studies (36). Tat28–35SL8-specific CD8
 T cells at an
E:T ratio of 1:10 markedly reduced SIV replication (55%) in
four of the five CD8 T-cell lines tested. Epitope-specific
CD8 T cells against Gag181–189CM9 were also effective and
exhibited levels of suppression in the range of 32 to 90%.
While Gag is generally viewed as a late protein, recent findings
have shown that Gag-specific epitopes can be recognized as
early as 2 hours after SIV infection (58a). This early presen-
tation advantage may contribute to the ability of Gag181–
189CM9 CD8 T cells to effectively suppress SIV replication.
The remaining five SIV-specific CD8 T-cell responses, including
CD8 T-cell lines against an early SIV epitope, Nef159–167YY9,
were largely ineffective at suppressing viral replication (Fig. 1).
In vivo, Nef159–167YY9 elicits an immunodominant CD8
 T-
cell response, with viral escape occurring as early as 4 weeks
postinfection (50, 58, 67). However, Nef159–167YY9-specific
CD8 T-cell lines from four different macaques, including two
elite controllers, failed to suppress viral replication. In addi-
tion, we found that CD8 T lymphocytes, which recognize two
different epitopes within the same viral protein, did not exhibit
similar suppressive properties. Both an immunodominant
Mamu-A*01-restricted epitope, Gag181–89CM9, and an immu-
nodominant Mamu-A*02-restricted epitope, Gag71–79GY9,
are located in Gag. However, only Gag181–189CM9-specific
CD8 T-cell lines consistently suppressed SIV replication
FIG. 3. Gag181–189CM9- and Tat28–35SL8-specific CD8
 T lymphocytes were unable to suppress the replication of an SIVmac239 escape variant.
(A) Amino acid sequences of the wild-type and variant epitopes located in Gag and Tat. (B) Intracellular Gag p27 staining of representative day
8 VSA results using effector and target cells at 1:10 infected with either wild-type SIVmac239 or an escape variant, SIVmac239. (C) Quantitative PCR
of viral RNA copies/ml on days 4, 6, and 8 of the same assay.
2630 LOFFREDO ET AL. J. VIROL.
50% (Fig. 1 and Table 2). Similar to previous studies (11, 62,
72), the functional avidity of cytokine reactivity did not appear
to correlate with antiviral efficacy in vitro (data not shown).
We also examined the impact that disease progression may
have on the ability of CD8 T cells to effectively suppress viral
replication. While Tat28–35SL8-specific CD8
 T cells were
more effective at suppressing SIV replication, we previously
observed animal-to-animal variability (36). However, this vari-
ability did not appear to directly reflect differences in the
disease statuses or viral loads of macaques at the time of cell
line generation (Table 2).
The effect of viral escape from CD8 T-cell responses is an
important consideration for vaccine development. Certain
high-frequency CD8 T-cell responses rapidly select for viral
escape, driving CD8 T-cell-susceptible viral sequences to ex-
tinction within 4 weeks of infection (3, 50, 58, 67). Recent
studies have also addressed the influence of escape on viral
fitness (17, 27, 33, 40, 41). To explore the role of viral escape
in antiviral efficacy, we generated a clone of SIVmac239 that
contained escape mutations in two Mamu-A*01-restricted
CD8 T-cell epitopes, Tat28–35SL8 and Gag181–189CM9 (17).
Tat28-35SL8- and Gag181–189CM9-specific CD8
 T cells did not
suppress the replication of this escape variant virus (Fig. 3).
This loss of antiviral efficacy was somewhat surprising for
Gag181–189CM9-specific CD8
 T cells, because the variant of
Gag181–189CM9 was well recognized in both IFN-/TNF- ICS
and IFN- ELISPOT assays (Fig. 2). Our data suggest that the
currently employed routine immunological assays neither ac-
curately predict the antiviral efficacy of CD8 T cells nor
measure the impact of viral escape on the ability of these cells
to suppress viral replication. Furthermore, similar cytokine
production readouts are currently being employed to detect
cross-clade CD8 T-cell responses induced by HIV infection
and vaccine immunogens (13, 21, 68). Our results suggest that
the correlation between cytokine production and antiviral
function is neither direct nor consistent. Therefore, while
CD8 T cells may release IFN- in response to peptides rep-
resenting several HIV clades, this does not necessarily indicate
that they can effectively suppress the replication of viruses in
these clades.
In this study, we used epitope-specific CD8 T-cell lines
rather than CD8 T-cell clones to reduce potential bias that
could result from studying cell populations with limited or no
T-cell receptor (TCR) diversity. Epitope-specific CD8 T-cell
populations with diverse clonotypic repertoires are observed in
HIV and SIV infection; indeed, TCR diversity may be benefi-
cial (10, 14, 29, 56). Complementary studies in our laboratory
using CD8 T-cell clones have shown that different clones
specific for a single peptide can vary in their abilities to sup-
press virus replication, underscoring the importance of TCR
diversity (11).
Previous studies of HIV and SIV demonstrated that epitope-
specific CD8 T lymphocytes suppress viral replication primar-
ily through direct cytolytic activity (20, 71, 72). In our investi-
gation, we did not directly measure the cytolytic activities of
our highly specific CD8 T-cell lines. While we cannot account
for potential variability in the cytolytic activity and its effect on
our VSA readouts, results from VSA and ICS assays displayed
similar trends over time (data not shown).
It is plausible that findings using our in vitro viral-suppres-
sion assay might be extrapolated to the ability to suppress
HIV/SIV replication in vivo. However, future investigations of
CD8 T-cell antiviral efficacy might benefit from modifications
of this assay. These include using higher multiplicities of in-
fection to mimic the massive infection and rapid loss of CD4
T cells at mucosal surfaces (35, 44). Emerging evidence also
suggests that CD8 T cells reactive to subdominant epitopes
may contribute significantly to the control of HIV and SIV
replication in vivo (16, 18a). More extensive evaluation of
these T-cell populations will be necessary.
Overall, our results outline clear differences in CD8 T-cell
efficacy and suggest that the antiviral efficacy of CD8 T cells
should be measured for individual epitopes and not general-
ized by protein. We found no supporting evidence for the idea
that CD8 T cells that recognize epitopes in early-expressed
viral proteins were more efficacious than those that recognize
epitopes in late-expressed proteins. However, recent findings
regarding Gag epitope expression show that these timing des-
ignations might not be as appropriate as was once thought
(58a). Furthermore, our findings indicate that routine immu-
nological assays are both indirect and inadequate for assessing
T-cell function and cross-reactivity. While ELISPOT and ICS
assays are widely accepted means to track CD8 T-cell fre-
quencies, these assays fail to differentiate among T-cell popu-
lations in terms of antiviral efficacy. The use of functional
assays in addition to standard immunogenicity assays should
enable us to more thoroughly evaluate candidate epitopes for
inclusion in future HIV vaccines.
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